Anika Therapeutics ANIK Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's non-cash lease expense?
- Anika Therapeutics (ANIK) reported non-cash lease expense of $464K in Q1 2026.
- How has Anika Therapeutics's non-cash lease expense changed year-over-year?
- Anika Therapeutics's non-cash lease expense decreased by 19.6% year-over-year, from $577K to $464K.
- What is the long-term trend for Anika Therapeutics's non-cash lease expense?
- Over 4 years (2021 to 2025), Anika Therapeutics's non-cash lease expense has grown at a 4.8% compound annual growth rate (CAGR), from $1.71M to $2.06M.
- What does non-cash lease expense mean?
- Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.